Infectious Agents and Cancer

unofficial impact factor 2.33
Search for
Advanced search
Infectious Agents and Cancer
Tools

This article is part of the supplement: Proceedings of the 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research

Open Access Oral presentation

Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab

K Dunleavy*, RF Little, AS Wayne, N Grant, S Pittaluga, ES Jaffe, S Steinberg, R Yarchoan, J Carrasquillo, J Janik and WH Wilson

  • * Corresponding author: K Dunleavy

Author Affiliations

Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA

For all author emails, please log on.

Infectious Agents and Cancer 2009, 4(Suppl 2):O9 doi:10.1186/1750-9378-4-S2-O9

Published: 17 June 2009

First paragraph (this article has no abstract)

The addition of rituximab to CHOP chemotherapy may augment tumor response but in patients with low CD4 counts, one study suggested that this benefit may be offset by increased infectious deaths (Kaplan. Blood 2005; 106:1538). We hypothesized that the addition of rituximab to EPOCH chemotherapy could improve tumor kill, allowing fewer cycles of treatment and therefore reducing toxicity.